A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The primary purpose of this study is to evaluate the safety and tolerability of Lpathomab in healthy volunteers. Additional endpoints include characterization of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity profiles of a single IV dose of Lpathomab in healthy volunteers.

Key facts

Study ID

NCT02341508

Run by

Lpath, Inc.

People needed

36

Starts

2015-09-01

Expected to finish

2016-03-01

Last updated by the study team

2016-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

Where it is running

• PRA Health Sciences — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.